H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Celldex (CLDX) to $50 from $80 and keeps a Buy rating on the shares following the Q1 report. The firm expects 2025 to be a year of continued execution across the company’s pipeline, and highlight the current status of the ongoing programs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Pipeline and Strong Financial Position Justify Buy Rating
- Celldex reports Q1 EPS (81c), consensus (74c)
- Optimistic Buy Rating for Celldex Driven by Promising Barzolvolimab Developments and Strong Financial Position
- Promising Phase 2 Results for Celldex’s Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating
- Celldex presents histology data from barzolvolimab study